J H Rubenstein1, J B Taylor. 1. Veterans Affairs Center of Excellence for Clinical Management Research, Ann Arbor, MI, USA. jhr@umich.edu
Abstract
BACKGROUND: Endoscopic screening has been proposed for patients with symptoms of gastro-oesophageal reflux disease (GERD) in the hope of reducing mortality from oesophageal adenocarcinoma. Assessing the net benefits of such a strategy requires a precise understanding of the cancer risk in the screened population. AIM: To estimate precisely the association between symptoms of GERD and oesophageal adenocarcinoma. METHODS: Systematic review and meta-analysis of population-based studies with strict ascertainment of exposure and outcomes. RESULTS: Five eligible studies were identified. At least weekly symptoms of GERD increased the odds of oesophageal adenocarcinoma fivefold (odds ratio = 4.92; 95% confidence interval = 3.90, 6.22), and daily symptoms increased the odds sevenfold (random effects summary odds ratio = 7.40, 95% confidence interval = 4.94, 11.1), each compared with individuals without symptoms or less frequent symptoms. Duration of symptoms was also associated with oesophageal adenocarcinoma, but with very heterogeneous results, and unclear thresholds. CONCLUSIONS: Frequent GERD symptoms are strongly associated with oesophageal adenocarcinoma. These results should be useful in developing epidemiological models of the development of oesophageal adenocarcinoma, and in models of interventions aimed at reducing mortality from this cancer. Published 2010. This article is a US Government work and is in the public domain in the USA.
BACKGROUND: Endoscopic screening has been proposed for patients with symptoms of gastro-oesophageal reflux disease (GERD) in the hope of reducing mortality from oesophageal adenocarcinoma. Assessing the net benefits of such a strategy requires a precise understanding of the cancer risk in the screened population. AIM: To estimate precisely the association between symptoms of GERD and oesophageal adenocarcinoma. METHODS: Systematic review and meta-analysis of population-based studies with strict ascertainment of exposure and outcomes. RESULTS: Five eligible studies were identified. At least weekly symptoms of GERD increased the odds of oesophageal adenocarcinoma fivefold (odds ratio = 4.92; 95% confidence interval = 3.90, 6.22), and daily symptoms increased the odds sevenfold (random effects summary odds ratio = 7.40, 95% confidence interval = 4.94, 11.1), each compared with individuals without symptoms or less frequent symptoms. Duration of symptoms was also associated with oesophageal adenocarcinoma, but with very heterogeneous results, and unclear thresholds. CONCLUSIONS: Frequent GERD symptoms are strongly associated with oesophageal adenocarcinoma. These results should be useful in developing epidemiological models of the development of oesophageal adenocarcinoma, and in models of interventions aimed at reducing mortality from this cancer. Published 2010. This article is a US Government work and is in the public domain in the USA.
Authors: D C Farrow; T L Vaughan; C Sweeney; M D Gammon; W H Chow; H A Risch; J L Stanford; P D Hansten; S T Mayne; J B Schoenberg; H Rotterdam; H Ahsan; A B West; R Dubrow; J F Fraumeni; W J Blot Journal: Cancer Causes Control Date: 2000-03 Impact factor: 2.506
Authors: David Armstrong; John K Marshall; Naoki Chiba; Robert Enns; Carlo A Fallone; Ronnie Fass; Roger Hollingworth; Richard H Hunt; Peter J Kahrilas; Serge Mayrand; Paul Moayyedi; William G Paterson; Dan Sadowski; Sander Jo Veldhuyzen van Zanten Journal: Can J Gastroenterol Date: 2005-01 Impact factor: 3.522
Authors: W H Chow; W J Blot; T L Vaughan; H A Risch; M D Gammon; J L Stanford; R Dubrow; J B Schoenberg; S T Mayne; D C Farrow; H Ahsan; A B West; H Rotterdam; S Niwa; J F Fraumeni Journal: J Natl Cancer Inst Date: 1998-01-21 Impact factor: 13.506
Authors: Adrian R McElholm; Amy-Jane McKnight; Chris C Patterson; Brian T Johnston; Laura J Hardie; Liam J Murray Journal: Gastroenterology Date: 2010-04-24 Impact factor: 22.682
Authors: Joel H Rubenstein; Hal Morgenstern; Daniel McConell; James M Scheiman; Philip Schoenfeld; Henry Appelman; Laurence F McMahon; John Y Kao; Val Metko; Min Zhang; John M Inadomi Journal: Gastroenterology Date: 2013-08-30 Impact factor: 22.682
Authors: William D Hazelton; Kit Curtius; John M Inadomi; Thomas L Vaughan; Rafael Meza; Joel H Rubenstein; Chin Hur; E Georg Luebeck Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-04-30 Impact factor: 4.254